Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 1

A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

NCT06702449 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation of clinical efficacy in females between and including 18-64 YOA.

Conditions Studied

Interventions

  • COMBINATION_PRODUCT Candidate UTI vaccine low dose formulation 1
  • COMBINATION_PRODUCT Candidate UTI vaccine low dose formulation 2
  • COMBINATION_PRODUCT Candidate UTI vaccine medium dose formulation 1
  • COMBINATION_PRODUCT Candidate UTI vaccine medium dose formulation 2
  • COMBINATION_PRODUCT Candidate UTI vaccine high dose formulation 1

Study Locations (8)

Washington

  • GSK Investigational Site — Seattle
  • GSK Investigational Site — Wenatchee

Other

  • GSK Investigational Site — Johannesburg
  • GSK Investigational Site — Soshanguve

Kansas

  • GSK Investigational Site — Lenexa

New Jersey

  • GSK Investigational Site — Secaucus

New York

  • GSK Investigational Site — Rochester

Texas

  • GSK Investigational Site — Weatherford

Trial Details

FieldValue
Enrollment Target 448 participants
Start Date 2024-11-19
Est. Completion 2027-05-31
Phase Phase 1

Sponsor

GlaxoSmithKline

558 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06702449

The ClinicalTrials.gov registry entry for NCT06702449 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 448 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 558 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Urinary Tract Infections appearing as the primary indexed condition, and to 5 interventions — of which Candidate UTI vaccine low dose formulation 1 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06702449 reports 8 study locations spanning 6 distinct geographic areas — top geographies include Washington, Other, Kansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06702449 about?

NCT06702449 is a clinical study titled "A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age". The purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation of clinical efficacy in females between and including 18-64 YOA.

What is the current status of trial NCT06702449?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 448 participants. The study started on 2024-11-19. Estimated completion is 2027-05-31.

What conditions does trial NCT06702449 study?

This clinical trial studies the following conditions: Urinary Tract Infections. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06702449?

The interventions under investigation include: Candidate UTI vaccine low dose formulation 1 (COMBINATION_PRODUCT), Candidate UTI vaccine low dose formulation 2 (COMBINATION_PRODUCT), Candidate UTI vaccine medium dose formulation 1 (COMBINATION_PRODUCT), Candidate UTI vaccine medium dose formulation 2 (COMBINATION_PRODUCT), Candidate UTI vaccine high dose formulation 1 (COMBINATION_PRODUCT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06702449?

This trial is sponsored by GlaxoSmithKline, which has 558 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06702449 being conducted?

This trial has 8 study locations across Kansas, New Jersey, New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial